SG Americas Securities LLC Has $11.62 Million Position in Insmed, Inc. $INSM

SG Americas Securities LLC grew its stake in Insmed, Inc. (NASDAQ:INSM) by 283.6% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 66,762 shares of the biopharmaceutical company’s stock after buying an additional 49,356 shares during the period. SG Americas Securities LLC’s holdings in Insmed were worth $11,619,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. CIBC Private Wealth Group LLC lifted its stake in shares of Insmed by 42.1% in the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 53 shares during the period. Stone House Investment Management LLC acquired a new stake in Insmed during the 3rd quarter valued at approximately $29,000. SBI Securities Co. Ltd. raised its holdings in Insmed by 404.9% during the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 166 shares during the last quarter. MassMutual Private Wealth & Trust FSB lifted its position in shares of Insmed by 59.6% in the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 217 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 81 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. boosted its stake in shares of Insmed by 169.7% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 240 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 151 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Morgan Stanley set a $166.00 target price on shares of Insmed in a research note on Friday, February 20th. Roth Mkm raised shares of Insmed to a “strong-buy” rating in a research report on Friday, January 23rd. TD Cowen set a $241.00 price target on Insmed in a report on Thursday, December 18th. The Goldman Sachs Group boosted their price objective on Insmed from $225.00 to $258.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Finally, Citigroup restated an “outperform” rating on shares of Insmed in a research report on Thursday, December 18th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $210.19.

Insmed Trading Down 1.6%

INSM opened at $145.30 on Friday. The company has a fifty day moving average price of $150.13 and a two-hundred day moving average price of $166.10. Insmed, Inc. has a 1-year low of $60.40 and a 1-year high of $212.75. The company has a market cap of $31.32 billion, a P/E ratio of -22.67 and a beta of 1.13. The company has a current ratio of 3.83, a quick ratio of 3.54 and a debt-to-equity ratio of 0.76.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). The company had revenue of $263.84 million for the quarter, compared to the consensus estimate of $263.97 million. Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.Insmed’s revenue for the quarter was up 152.6% compared to the same quarter last year. During the same period last year, the company earned ($1.32) EPS. Analysts predict that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Insider Activity at Insmed

In other news, insider Orlov S. Nicole Schaeffer sold 87,290 shares of the company’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $175.20, for a total transaction of $15,293,208.00. Following the transaction, the insider directly owned 41,754 shares of the company’s stock, valued at $7,315,300.80. This represents a 67.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO William Lewis sold 19,215 shares of the stock in a transaction on Monday, January 12th. The stock was sold at an average price of $169.00, for a total value of $3,247,335.00. Following the completion of the transaction, the chief executive officer owned 306,891 shares in the company, valued at approximately $51,864,579. This represents a 5.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 189,651 shares of company stock worth $31,533,654. Corporate insiders own 3.00% of the company’s stock.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.